3 recruiting, 2 active not recruiting, 2 completed, 2 unknown. 6 Phase 3, 2 Phase 1, 2 Phase 2, 1 Not applicable.
Follow Calcium levofolinate: new trials by email Literature Review of Calcium levofolinate trials Research Report on Calcium levofolinate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure BL-M07D1, Oxaliplatin, Calcium levofolinate - Biliary Tract Cancer | Phase 3 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 398 | 2026-07-07 | 2026-07-24 |
| A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01) BL-B01D1, Oxaliplatin, Calcium levofolinate - Biliary Tract Cancer | Phase 3 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 538 | 2026-06-29 | 2026-07-24 |
| Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) Pembrolizumab, Sacituzumab Tirumotecan (sac-TMT), Capecitabine - Gastroesophageal Junction, Gastroesophageal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 160 | 2024-09-20 | 2026-10-07 |
| Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors Futibatinib, Pembrolizumab, Cisplatin - Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma | Phase 2 | Active not recruiting | Taiho Oncology, Inc. | 53 | 2023-07-13 | 2026-09-01 |
| Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma NP137, Oxaliplatin, Irinotecan - Pancreatic Ductal Adenocarcinoma | Phase 1 | Completed | University Hospital, Grenoble | 43 | 2023-03-28 | 2026-05-19 |
| Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014). Pembrolizumab, Lenvatinib, Cisplatin - Metastatic Esophageal Squamous Cell Carcinoma | Phase 3 | Terminated | Merck Sharp & Dohme LLC | 863 | 2021-07-28 | 2026-08-21 |
| Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB Bevacizumab, Cetuximab, 5-FU - Colorectal Cancer, Metastatic Colorectal Cancer | Phase 3 | Active not recruiting | Azienda USL Reggio Emilia - IRCCS | 280 | 2021-04-30 | 2026-07-24 |
| Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975) pembrolizumab, placebo, cisplatin - Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC) | Phase 3 | Completed | Merck Sharp & Dohme LLC | 703 | 2020-02-28 | 2026-07-22 |
| mFOLFOX Versus mFOLFIRI Versus FOLFPTX as First-line Treatment in AGC or EGJA Fluorouracil, Oxaliplatin, Irinotecan - Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction | Not applicable | Unknown | Fujian Cancer Hospital | 150 | 2017-02-10 | 2017-02-07 |
| Adjuvant Chemotherapy Combined With Huaier Granule for Treating High-risk Stage II, Stage III Colorectal Cancer Huaier Granule, Oxaliplatin, Calcium folinate - Colorectal Cancer | Phase 3 | Unknown | Sixth Affiliated Hospital, Sun Yat-sen University | 230 | 2016-06-01 | 2016-06-08 |
Esophageal Squamous Cell Carcinoma (3) · Parkinson Disease 4, Autosomal Dominant Lewy Body (3) · Adenocarcinoma Of Esophagus (2) · Biliary Tract Neoplasms (2) · Colorectal Neoplasms (2) · Esophageal Neoplasms (2) · Neoplasm Metastasis (1) · Pancreatic Neoplasms (1)
Merck Sharp & Dohme LLC (3) · Sichuan Baili Pharmaceutical Co., Ltd. (2) · Azienda USL Reggio Emilia - IRCCS (1) · Fujian Cancer Hospital (1) · Sixth Affiliated Hospital, Sun Yat-sen University (1) · Taiho Oncology, Inc. (1) · University Hospital, Grenoble (1)
China (7) · France (5) · Italy (4) · United States (4) · Chile (3) · Germany (3) · South Korea (3) · Taiwan (3) · Argentina (2) · Brazil (2) · Canada (2) · Denmark (2) · Guatemala (2) · Hong Kong (2) · Hungary (2)
Erika Gervasi (1) · Irene De Simone (1) · Jianwei Yang (1) · Xiaojian Wu, Ph.D. (1)
PMID 20718753, PMID 22895629, PMID 23599758, PMID 25077927, PMID 33533655, PMID 38695479, PMID 42020751
2019 (1), 2023 (1)